Structural determinants of the capacity of heparin to inhibit collagen synthesis in 21-day fetal rat calvariae
Open Access
- 1 November 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 5 (11) , 1127-1133
- https://doi.org/10.1002/jbmr.5650051106
Abstract
Earlier work from our laboratory demonstrated that heparin inhibits type I collagen and DNA synthesis in fetal rat calvariae in vitro. In this paper we have analyzed the structural features of heparin that determine its inhibitory effect on collagen synthesis. These experiments were performed using unmodified heparins and low-molecular-weight heparins from different manufacturers, nonheparin glycosaminoglycans, desulfated heparins, anticoagulant and nonanticoagulant heparin, and chemically defined heparin oligosaccharides. Low-molecular-weight heparin (Mr 3700–5100) inhibited collagen synthesis, but oligosaccharides (disaccharides to decasaccharide, Mr 665–3000) did not. The glycosaminoglycans chondroitin sulfate B, heparan sulfate, and hyaluronic acid did not alter collagen synthesis but dextran sulfate was as inhibitory as unmodified heparin. Nonanticoagulant as well as anticoagulant low-molecular-weight heparin fractions inhibited collagen synthesis. Modification of heparin by total desulfation, O-desulfation, or N-desulfation and re-N-acetylation resulted in the loss of inhibitory property, suggesting that the degree of sulfation contributed to heparin's inhibitory effect. Low-molecular-weight heparins from different manufacturers were just as inhibitory as native heparin on collagen synthesis. We therefore conclude that low-molecular-weight heparin compounds offer no protection against heparin-induced osteoporosis. Our findings also suggest that the size and sulfation of a heparin-derived oligosaccharide contribute to its ability to inhibit collagen synthesis in bone.Funding Information
- NIH (AR38933)
This publication has 36 references indexed in Scilit:
- A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip SurgeryNew England Journal of Medicine, 1986
- Neurite outgrowth induced by an endothelial cell mitogen isolated from retina.The Journal of cell biology, 1986
- Heparin protects basic and acidic FGF from inactivationJournal of Cellular Physiology, 1986
- Inhibition of rat cervical epithelial cell growth by heparin and its reversal by EGFJournal of Cellular Physiology, 1985
- The Mast Cell and BonePublished by Wolters Kluwer Health ,1985
- Rationale Behind the Development of Low Molecular Weight Heparin DerivativesSeminars in Thrombosis and Hemostasis, 1985
- Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cellsJournal of Cellular Physiology, 1984
- Regulation of Bone FormationNew England Journal of Medicine, 1983
- Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growthThe Journal of cell biology, 1981
- Heparin Enhancement of Factors Stimulating Bone Resorption in Tissue CultureScience, 1965